Company: ANIX
Filing Date: 2025-01-10
Form Type: S-8
Source: 0001493152-25-001798
Chunk: 42

Company: Anixa Biosciences Inc
Filing Date: 2025-01-10
Form: S-8
Chunk 42
---
 stockholders’ ownership interests in our company and have an adverse impact on the price of our common stock.

In addition, sales of a substantial amount of our common stock in the public market, or the perception that these sales may occur, could reduce the market price of our common stock. This could also impair our ability to raise additional capital through the sale of our securities.

Any actual or anticipated sales of shares by our stockholders may cause the trading price of our common stock to decline. The sale of a substantial number of shares of our common stock by our stockholders, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.

We may fail to meet market expectations because of fluctuations in quarterly operating results, which could cause the price of our common stock to decline.

Our reported revenues and operating results have fluctuated in the past and may continue to fluctuate significantly from quarter to quarter in the future, specifically as we continue to devote our resources towards our CAR-T cancer therapeutics and our cancer vaccines. It is possible that in future periods, we will have no revenue or, in any event, revenues could fall below or expenses could rise above the expectations of securities analysts or investors, which could cause the market price of our common stock to decline. The following are among the factors that could cause our operating results to fluctuate significantly from period to period:

| ● | patient                                   
 enrollment rates for our clinical trials; |

| 25 |

| ● | delays                                                                                                                            
 with respect to our clinical trials;                                                                                              |
| ● | clinical                                                                                                                          
 trial results relating to our CAR-T cancer therapeutics;                                                                          |
| ● | clinical                                                                                                                          
 trial results relating to our breast cancer vaccine;                                                                              |
| ● | results                                                                                                                           
 of pre-clinical studies relating to our ovarian cancer vaccine;                                                                   |
| ● | results                                                                                                                           
 of our new vaccine discovery efforts;                                                                                             |
| ● | progress                                                                                                                          
 with regulatory authorities towards the certification/approval of our CAR-T cancer therapeutics, our breast cancer vaccine or our 
 ovarian cancer vaccine; and                                                                                                       |
| ● | costs                                                                                                                             
 related to acquisitions, alliances and licenses.                                                                                  |

Biotechnology company stock prices are especially volatile, and this volatility may depress the price of our common stock.

The stock market has experienced significant price and volume fluctuations, and the market prices of biotechnology companies have been highly volatile. We believe